Par Pharmaceutical Receives NDA Approval for Vasostrict, Starts Shipping it Out

Par Pharmaceutical said the FDA has approved its NDA for Vasostrict injection, making it the first product of its kind to win approval.

Vasostrict (vasopressin) is indicated to increase blood pressure in adults with vasodilatory shock, such as post-cardiotomy or sepsis, who remain hypotensive despite fluids and catecholamines.

Par said it has started shipping the drug, which is packaged in cartons of 25 multi-dose vials. — Jonathon Shacat

Originally appeared in Drug Industry Daily, the pharmaceutical industry’s number one source for regulatory news and information. Click here for more information.